Signaturefd LLC Acquires 725 Shares of Hologic, Inc. (NASDAQ:HOLX)

Signaturefd LLC grew its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 58.8% in the fourth quarter, Holdings Channel.com reports. The firm owned 1,959 shares of the medical equipment provider’s stock after buying an additional 725 shares during the period. Signaturefd LLC’s holdings in Hologic were worth $140,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in HOLX. Qube Research & Technologies Ltd boosted its position in Hologic by 117.2% during the third quarter. Qube Research & Technologies Ltd now owns 1,378,258 shares of the medical equipment provider’s stock worth $95,651,000 after purchasing an additional 743,557 shares during the period. Assenagon Asset Management S.A. boosted its position in shares of Hologic by 90.4% in the third quarter. Assenagon Asset Management S.A. now owns 845,493 shares of the medical equipment provider’s stock valued at $58,677,000 after acquiring an additional 401,486 shares during the period. Victory Capital Management Inc. boosted its position in shares of Hologic by 8.9% in the third quarter. Victory Capital Management Inc. now owns 4,838,090 shares of the medical equipment provider’s stock valued at $335,763,000 after acquiring an additional 393,371 shares during the period. Clearbridge Investments LLC bought a new position in shares of Hologic in the third quarter valued at approximately $25,398,000. Finally, American Century Companies Inc. boosted its position in shares of Hologic by 35.5% in the third quarter. American Century Companies Inc. now owns 1,080,073 shares of the medical equipment provider’s stock valued at $74,957,000 after acquiring an additional 283,241 shares during the period. Institutional investors own 94.73% of the company’s stock.

Hologic Trading Up 0.4 %

HOLX stock opened at $75.98 on Monday. The company has a market capitalization of $17.83 billion, a PE ratio of 36.01, a price-to-earnings-growth ratio of 2.57 and a beta of 1.00. Hologic, Inc. has a one year low of $64.02 and a one year high of $87.88. The company’s 50 day moving average price is $76.03 and its two-hundred day moving average price is $72.82. The company has a debt-to-equity ratio of 0.55, a quick ratio of 3.18 and a current ratio of 3.89.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings results on Thursday, February 1st. The medical equipment provider reported $0.98 EPS for the quarter, topping the consensus estimate of $0.95 by $0.03. The firm had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $989.32 million. Hologic had a net margin of 12.98% and a return on equity of 18.91%. The business’s revenue was down 5.7% compared to the same quarter last year. During the same period last year, the firm posted $1.07 earnings per share. As a group, analysts predict that Hologic, Inc. will post 4.01 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Hologic news, Director Scott T. Garrett sold 16,441 shares of Hologic stock in a transaction that occurred on Thursday, March 14th. The shares were sold at an average price of $75.50, for a total transaction of $1,241,295.50. Following the transaction, the director now directly owns 48,611 shares of the company’s stock, valued at $3,670,130.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, Director Charles J. Dockendorff sold 1,465 shares of Hologic stock in a transaction on Friday, March 8th. The shares were sold at an average price of $76.21, for a total value of $111,647.65. Following the transaction, the director now directly owns 1,572 shares of the company’s stock, valued at $119,802.12. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Scott T. Garrett sold 16,441 shares of Hologic stock in a transaction on Thursday, March 14th. The stock was sold at an average price of $75.50, for a total transaction of $1,241,295.50. Following the completion of the transaction, the director now directly owns 48,611 shares in the company, valued at $3,670,130.50. The disclosure for this sale can be found here. Insiders own 1.75% of the company’s stock.

Wall Street Analyst Weigh In

HOLX has been the subject of a number of analyst reports. StockNews.com lowered shares of Hologic from a “buy” rating to a “hold” rating in a research report on Friday, March 8th. UBS Group raised their price objective on shares of Hologic from $78.00 to $79.00 and gave the company a “neutral” rating in a research report on Friday, February 2nd. Citigroup upgraded shares of Hologic from a “neutral” rating to a “buy” rating and raised their price objective for the company from $80.00 to $95.00 in a research report on Wednesday, April 3rd. Raymond James lifted their target price on shares of Hologic from $85.00 to $88.00 and gave the company an “outperform” rating in a research report on Friday, February 2nd. Finally, Needham & Company LLC reiterated a “buy” rating and set a $90.00 target price on shares of Hologic in a research report on Wednesday, April 10th. Six investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $87.00.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.